Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.
Khoo SH, Fitzgerald R, Fletcher T, Ewings S, Jaki T, Lyon R, Downs N, Walker L, Tansley-Hancock O, Greenhalf W, Woods C, Reynolds H, Marwood E, Mozgunov P, Adams E, Bullock K, Holman W, Bula MD, Gibney JL, Saunders G, Corkhill A, Hale C, Thorne K, Chiong J, Condie S, Pertinez H, Painter W, Wrixon E, Johnson L, Yeats S, Mallard K, Radford M, Fines K, Shaw V, Owen A, Lalloo DG, Jacobs M, Griffiths G. Khoo SH, et al. Among authors: wrixon e. J Antimicrob Chemother. 2021 Nov 12;76(12):3286-3295. doi: 10.1093/jac/dkab318. J Antimicrob Chemother. 2021. PMID: 34450619 Free PMC article. Clinical Trial.
AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial.
Griffiths G, Fitzgerald R, Jaki T, Corkhill A, Marwood E, Reynolds H, Stanton L, Ewings S, Condie S, Wrixon E, Norton A, Radford M, Yeats S, Robertson J, Darby-Dowman R, Walker L, Khoo S; UK NIHR community. Griffiths G, et al. Among authors: wrixon e. Trials. 2020 Jun 19;21(1):544. doi: 10.1186/s13063-020-04473-1. Trials. 2020. PMID: 32560744 Free PMC article.
Pelargonium sidoides root extract for the treatment of acute cough due to lower respiratory tract infection in adults: a feasibility double-blind, placebo-controlled randomised trial.
Willcox M, Simpson C, Wilding S, Stuart B, Soilemezi D, Whitehead A, Morgan A, Wrixon E, Zhu S, Yao G, Webley F, Yan R, Bostock J, Bell M, Griffiths G, Leydon G, Little P, Butler C, Hay AD, Moore M. Willcox M, et al. Among authors: wrixon e. BMC Complement Med Ther. 2021 Jan 29;21(1):48. doi: 10.1186/s12906-021-03206-4. BMC Complement Med Ther. 2021. PMID: 33514367 Free PMC article. Clinical Trial.
HATRIC: a study of Pelargonium sidoides root extract EPs®7630 (Kaloba®) for the treatment of acute cough due to lower respiratory tract infection in adults-study protocol for a double blind, placebo-controlled randomised feasibility trial.
Whitehead A, Simpson C, Willcox M, Webley F, Hay AD, Butler C, Yao L, Wrixon E, Bell M, Bostock J, Little P, Griffiths G, Moore M. Whitehead A, et al. Among authors: wrixon e. Pilot Feasibility Stud. 2019 Jul 31;5:98. doi: 10.1186/s40814-019-0478-6. eCollection 2019. Pilot Feasibility Stud. 2019. PMID: 31384480 Free PMC article.